Sakalis Vasileios, Gkotsi Anastasia, Mylonaki Efrosyni, Pantzaki Aphroditi, Charalambous Stavros, Rombis Vasileios
Department of Urology, Hippokrateion General Hospital of Thessaloniki, Thessaloniki;
Rare Tumors. 2011 Jul 11;3(3):e30. doi: 10.4081/rt.2011.e30. Epub 2011 Jul 29.
Small cell carcinoma (SCC) or microcytic carcinoma of the urinary bladder is a rare entity comprising approximately 0.5% of all bladder tumors. Due to its rarity, no prospective studies evaluating the most effective treatment have been published in the medical literature. Several cases of bladder SCC have been presented so far. We describe our case report and we revise the recent literature. Our patient was diagnosed with pure bladder SCC and prostatic adenocarcinoma. After the initial and complete transurethral resection of the bladder tumour (TUR-BT), he underwent a thorax and mediastinum computer tomography (CT) examination to exclude primary pulmonary small cell carcinoma and a bone scan scintigraphy for staging purposes. He received a three 14-day cycles of Cisplatin-containing chemotherapeutic schema and a single dose of Luteinizing-Hormone Releasing hormone (LHRH) analogue injection after 14 days of bicalutamide administration. The patient is followed for 24 months without any signs of bladder SCC recurrence or biochemical or local relapse from prostatic adenocarcinoma.
膀胱小细胞癌（SCC）或微细胞癌是一种罕见的实体瘤，约占所有膀胱肿瘤的0.5%。由于其罕见性，医学文献中尚未发表评估最有效治疗方法的前瞻性研究。到目前为止，已经报道了几例膀胱SCC病例。我们描述了我们的病例报告并回顾了近期文献。我们的患者被诊断为单纯性膀胱SCC和前列腺腺癌。在最初对膀胱肿瘤进行完全经尿道切除术（TUR-BT）后，他接受了胸部和纵隔计算机断层扫描（CT）检查以排除原发性肺小细胞癌，并进行了骨扫描闪烁显像以进行分期。他接受了三个为期14天的含顺铂化疗方案，并在服用比卡鲁胺14天后注射了一剂促黄体生成素释放激素（LHRH）类似物。对该患者进行了24个月的随访，没有膀胱SCC复发或前列腺腺癌生化或局部复发的任何迹象。
